Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.

@article{Noonan2016RandomizedP2,
  title={Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.},
  author={Anne Mary Noonan and Matthew R. Farren and Susan Michelle Geyer and Ying Huang and S. Mchakra Tahiri and Daniel H Ahn and Sameh E Mikhail and Kristen K Ciombor and Shubham Pant and Santiago Aparo and Jennifer L Sexton and John Marshall and Thomas A. Mace and Christina Sing-Ying Wu and Bassel F El-Rayes and Cynthia Dawn Timmers and James A. Zwiebel and Gregory B. Lesinski and Miguel Angel Villalona-Calero and Tanios S. Bekaii-Saab},
  journal={Molecular therapy : the journal of the American Society of Gene Therapy},
  year={2016},
  volume={24 6},
  pages={1150-1158}
}
Pelareorep causes oncolysis in tumor cells with activated Ras. We hypothesized that pelareorep would have efficacy and immunomodulatory activity in metastatic pancreatic adenocarcinoma (MPA) when combined with carboplatin and paclitaxel. A randomized phase 2 study (NCT01280058) was conducted in treatment-naive patients with MPA randomized to two treatment arms: paclitaxel/carboplatin + pelareorep (Arm A, n = 36 evaluable patients) versus paclitaxel/carboplatin (Arm B, n = 37 evaluable patients… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 20 times over the past 90 days. VIEW TWEETS
19 Citations
40 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 40 references

National Cancer Institute: Bethesda, MD

  • N N Howlader, M Krapcho, J Garshell, D Miller, SF Altekruse
  • SEER Cancer Statistics Review,
  • 2014

Similar Papers

Loading similar papers…